Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
ACCELERON PHARMA INC (XLRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/22/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACCELERON PHARMA INC.",
"."
11/04/2021 8-K Quarterly results
Docs: "Acceleron Reports Third Quarter 2021 Financial Results - Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® -"
10/27/2021 8-K Results of Operations and Financial Condition  Interactive Data
09/30/2021 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "AGREEMENT AND PLAN OF MERGER",
"Merck to Acquire Acceleron Pharma Inc."
08/05/2021 8-K Quarterly results
07/28/2021 8-K Results of Operations and Financial Condition  Interactive Data
06/22/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
05/19/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/13/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association Scientific Sessions – Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 –",
"Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association Scientific Sessions – Treatment with sotatercept in first set of patients in the ongoing SPECTRA Phase 2 trial was associated with substantial improvements in hemodynamics, exercise tolerance and exercise capacity at week 24 –",
"THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE"
11/05/2020 8-K Quarterly results
Docs: "Acceleron Reports Third Quarter 2020 Operating and Financial Results - Acceleron recognized approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL® -"
11/05/2020 8-K Results of Operations and Financial Condition  Interactive Data
10/02/2020 8-K Quarterly results
09/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/06/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
07/01/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
06/24/2020 8-K Quarterly results
06/04/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
04/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2013"
04/07/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/06/2020 8-K Other Events  Interactive Data
03/09/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy